Indivior (NASDAQ:INDV) Price Target Raised to $45.00

Indivior (NASDAQ:INDV) had its price objective boosted by Barclays from $43.00 to $45.00 in a report released on Wednesday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other brokerages have also weighed in on INDV. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 2nd. Weiss Ratings cut Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, September 24th. Finally, Craig Hallum reissued a “buy” rating and issued a $53.00 price objective on shares of Indivior in a report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $46.40.

Indivior Price Performance

Shares of NASDAQ:INDV opened at $35.37 on Wednesday. Indivior has a 1 year low of $27.68 and a 1 year high of $42.81. The firm has a market capitalization of $4.17 billion, a PE ratio of 9.88 and a beta of 0.87. The business’s 50 day moving average price is $35.20 and its 200-day moving average price is $35.62.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Thursday, October 29th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.26. The business had revenue of $356.00 million during the quarter, compared to analyst estimates of $329.35 million. Indivior had a negative return on equity of 418.04% and a net margin of 32.75%. As a group, analysts expect that Indivior will post 3.66 earnings per share for the current year.

Indivior Dividend Announcement

The business also recently declared a special dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 30th will be issued a $8.13 dividend.

Insider Transactions at Indivior

In other news, CAO Woodrow D. Anderson acquired 1,500 shares of Indivior stock in a transaction that occurred on Thursday, August 27th. The stock was purchased at an average cost of $35.69 per share, with a total value of $53,535.00. Following the completion of the acquisition, the chief accounting officer owned 27,638 shares in the company, valued at $986,400.22. This trade represents a 5.74% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.74% of the company’s stock.

Institutional Investors Weigh In On Indivior

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. HighTower Advisors LLC acquired a new position in Indivior in the second quarter valued at approximately $3,409,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Indivior during the second quarter valued at approximately $7,988,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Indivior during the 2nd quarter worth approximately $3,332,000. Cookson Peirce & Co. Inc. acquired a new stake in shares of Indivior during the 2nd quarter worth approximately $1,390,000. Finally, Wellington Management Group LLP acquired a new stake in shares of Indivior during the 2nd quarter worth approximately $1,870,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior PLC (NASDAQ:INDV) is a global pharmaceutical company focused on developing and commercializing medicines for substance use disorders and serious mental health conditions. Its portfolio is centered on treatments for opioid use disorder, opioid overdose, and related medical needs.

The company’s principal products include Sublocade, an extended-release buprenorphine injection for opioid use disorder; Suboxone, a buprenorphine and naloxone treatment available in film and other formulations; and Opvee, a nalmefene nasal spray intended for the emergency treatment of known or suspected opioid overdose.